Bivona Lab

Research focus

NIH R01 · 2024

Characterization of YAP as a rational companion target in lung cancer

PROJECT ABSTRACT. Lung cancer is the leading cause of cancer mortality worldwide, with non-small cell lung cancer (NSCLC) the predominant histologic subtype of lung cancer and lung adenocarcinoma the major subset of NSCLC. Despite clinical progress with the use of targeted therapies, drug resistance remains a problem that limits patient survival. A less well understood aspect of the evolution of drug resistance is the drug tolerant, “persister” cell state, in which a subpopulation of cancer cells survives initial targeted treatment to form a minimal residual disease (MRD) reservoir that is a precursor to acquired resistance. We propose an innovative, multidisciplinary and collaborative…

From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.